Page 181 - 2019_07 resto del Mondo-web

Performance of AL cardiac staging systems
10. Merlini G, Lousada I, Ando Y, et al. Rationale, application and clinical qualifica- tion for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979– 1986.
11. Dispenzieri A, Gertz MA, Kumar SK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart Br Card Soc. 2014;100(5): 383–388.
12. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15): 2325–2332.
13. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
14. Mohty D, Petitalot V, Magne J, et al. Left atrial function in patients with light chain amyloidosis: a transthoracic 3D speckle tracking imaging study. J Cardiol. 2018;71(4):419–427.
15. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic pep- tide is a sensitive marker of myocardial dys- function in AL amyloidosis. Circulation. 2003;107(19):2440–2445.
16. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac tro- ponins. Lancet. 2003;361(9371):1787–1789.
17. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging sys- tem for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
18. Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloi-
dosis by the high-sensitivity troponin T
assay. Blood. 2010;116(14):2455–2461.
19. Dispenzieri A, Gertz MA, Saenger A, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognosti- cation in patients with systemic AL amyloi- dosis independent of NT-proBNP and tro- ponin T. Am J Hematol. 2015;90(6):524–528. 20. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac tro- ponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Blood. 2010;116(18):3426–3430.
21. Kumar S, Dispenzieri A, Lacy MQ, et al.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac bio- markers and serum free light chain measure- ments. J Clin Oncol. 2012;30(9):989–995.
22. Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc. 2008;83(3):297–303.
23. Kastritis E, Dimopoulos MA. Recent advances in the management of AL amyloi- dosis. Br J Haematol. 2016;172(2): 170–186.
24. Potter JM, Simpson AJ, Kerrigan J, et al. The relationship of plasma creatinine (as eGFR) and high-sensitivity cardiac troponin and NT-proBNP concentrations in a hospital and community outpatient population. Clin Biochem. 2017;50(15):813–815.
25. Chen M, Gerson H, Eintracht S, Nessim SJ, MacNamara E. Effect of hemodialysis on levels of high-sensitivity cardiac troponin T. Am J Cardiol. 2017;120(11):2061–2064.
26. Kristensen SL, Jhund PS, Mogensen UM, et al. Prognostic value of N-terminal pro-B- Type natriuretic peptide levels in heart fail- ure patients with and without atrial fibrilla- tion. Circ Heart Fail. 2017;10(10):e004409.
27. Thackray SDR, Witte K, Ghosh J, et al. N-
terminal brain natriuretic peptide as a screening tool for heart failure in the pace- maker population. Eur Heart J. 2006;27(4): 447–453.
28. deFilippi CR, Herzog CA. Interpreting car- diac biomarkers in the setting of chronic kid- ney disease. Clin Chem. 2017; 63(1):59–65.
29. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
30. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3): 515–526.
31. Gerds TA, Schumacher M. Consistent esti- mation of the expected Brier score in general survival models with right-censored event times. Biom J Biom. Z 2006;48(6):1029– 1040.
32. Gerds TA, Kattan MW, Schumacher M, Yu C. Estimating a time-dependent concor- dance index for survival prediction models with covariate dependent censoring. Stat Med. 2013;32(13):2173–2184.
33. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10(9): 824–839.
34. Manzano-Fernández S, Januzzi JL, Boronat- García M, et al. Impact of kidney dysfunc- tion on plasma and urinary N-terminal pro- B-type natriuretic peptide in patients with acute heart failure. Congest Heart Fail. 2010;16(5):214–220.
35. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799- 2806.
36. Muchtar E, Therneau TM, Gertz MA, et al. Can we pick a winner in immunoglobulin light chain amyloidosis staging systems? ISA. Abstract 2018;PC073.
haematologica | 2019; 104(7)
1459